Listed on the Taipei Exchange (TPEx), classified under Healthcare. This page collects the company's annual reports and investor conference materials, with files served directly by the Market Observation Post System (MOPS).
Taiwanese listed companies hold investor conferences (法人說明會) to present quarterly results. Presentation decks are filed with MOPS, most in both languages.
本公司受邀參加美國糖尿病學會（American Diabetes Association, ADA）舉辦之2026年Innovation Hub(簡報時間為當地115年6月7日下午2點10分)，本公司全球首創糖尿病足潰瘍創新產品 ON101，獲選為本屆全球創新頂尖 15 強。將向全球糖尿病領域專家、臨床醫師及潛在合作夥伴口頭報告 ON101 在糖尿病足潰瘍治療上的臨床突破成果與顯著優勢，以及減少糖尿病患截肢風險的重大臨床價值
Agenda as filed by the company, in Chinese only.
說明本公司重要新藥研發進度與營運現況。連結https://pse.is/8xz4cd
Agenda as filed by the company, in Chinese only.
本公司受邀參加J.P. Morgan舉辦之第44屆Healthcare Conference(簡報時間為當地115年1月15日上午9點30分)，會中將說明本公司經營績效、營運現況及未來展望等。
Agenda as filed by the company, in Chinese only.
說明本公司重要新藥研發進度與營運現況。連結http://bit.ly/3XLMZgR
Agenda as filed by the company, in Chinese only.
說明本公司重要新藥研發進度與營運現況。連結https://bit.ly/4ftqQfa
Agenda as filed by the company, in Chinese only.
(1) 合一生技與中天（上海）共同研發的廣效抗病毒小核酸新藥 SNS812，憑藉創新的機制與在臨床的顯著療效，於2025 年度美國胸腔醫學會（American Thoracic Society, ATS），獲選進行SNS812的最新臨床試驗成果口頭報告。 (2) ATS 年會為全球呼吸醫學領域最具影響力的國際學術盛會，涵蓋肺部疾病、重症醫學與睡眠醫學三大領域，每年約有 14,000 名來自全球的肺部醫學、重症醫學與睡眠醫學領域的臨床醫師、研究人員、護理師、呼吸治療師以及其他醫療保健專業人士與產業代表參與，聚焦於最新的科學研究、臨床創新與全球公共衛生挑戰。
Agenda as filed by the company, in Chinese only.
說明本公司重要新藥研發進度與營運現況。連結http://bit.ly/42LOK0H
Agenda as filed by the company, in Chinese only.
本公司受邀參加J.P. Morgan、UC Berkeley合辦之Healthcare Conference Taipei 2025，會中將說明本公司經營績效、營運現況及未來展望等。
Agenda as filed by the company, in Chinese only.
本公司受邀參加J.P. Morgan舉辦之第43屆Healthcare Conference(簡報時間為當地114年1月16日下午2點45分)，會中將說明本公司經營績效、營運現況及未來展望等。
Agenda as filed by the company, in Chinese only.
Every financial year in the table above links straight to the PDF filed with the Market Observation Post System (MOPS), Taiwan's statutory disclosure platform. 2 years are available in English, within a range covering 2024 to 2025.
Filing an English annual report is only mandatory for larger Taiwanese issuers; smaller companies and those on the Emerging Stock Board file in Chinese. Where no English edition exists this site links the Chinese PDF rather than leaving the year blank, so you can still reach the document.
It is the Taiwanese equivalent of an earnings call or analyst briefing. Listed companies present quarterly results and outlook, and file the presentation deck with MOPS — usually in both Chinese and English. Many also publish a webcast recording.
Taiwanese issuers file quarterly financial reports plus an annual report, and publish monthly revenue figures — a disclosure cadence that is more frequent than Hong Kong or Singapore. Financial years are numbered using the ROC calendar (ROC 114 = 2025); this site shows both.
